A Non-Randomized Phase II Research Study of M6620 (VX-970) in Selected Solid Tumors to Inhibit the ATR Enzyme.

About the Study

This clinical trial is studying how well M6620 works in treating patients with advanced solid tumors. M6620 is a drug designed to block the ATR enzyme. ATR repairs damaged DNA. In cancer, ATR may protect the cancer cells by helping them repair damage. Blocking ATR may keep cancers from repairing their damaged DNA; slowing the growth of, or killing cancer cells. The study is open to people with advanced solid tumors and a BRCA1, BRCA2 or ATM mutation. The study will be recruiting people with different types of cancer, including people with advanced solid tumors and a BRCA1, BRCA2 or ATM mutation. 

UPDATE: THIS STUDY IS NO LONGER ENROLLING PATIENTS.

Type of Study

• This is a non-randomized, open-label study.  All patients who enroll in the trial will receive the study medication.

What the Study Entails

• Participants will receive M6620 intravenously (IV) over 60 minutes on Days 1, 4, 8, 11, 15, 18, 22, and 25 on a 28-day cycle
• This cycles repeats every 28 days in the absence of disease progression
• After 16 weeks (4 cycles), patients may receive M6620 weekly on days 1, 8, 15, and 22
• Undergo on-treatment biopsy at Day 15

Study Locations

The following are participating institutions:

• Massachusetts
  • Boston: Dana-Farber Cancer Institute
    • Contact Geoffrey I. Shapiro, MD by email 
  • Boston: Beth Israel Deaconess Medical Center 
    • Contact Glen Weiss, MD by email
  • Boston: Massachusetts General Hospital Cancer Center:
    • Contact Gregory M. Cote, MD, PhD, by phone: 617-724-4000 or by email
  • Boston: Boston Children Hospital:
    • Contact Katherine Janeway, MD by email